An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease

Trial Profile

An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Latrepirdine (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Medivation
  • Most Recent Events

    • 09 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 17 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned number of patients changed from 20 to 21 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top